Bio-nanocapsules for <i>In vivo</i> Pinpoint Drug Delivery

DOI DOI Web Site Web Site PubMed 2 Citations 70 References Open Access
  • JUNG Joohee
    The Institute of Scientific and Industrial Research, Osaka University The Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST)
  • KASUYA Takeshi
    The Institute of Scientific and Industrial Research, Osaka University
  • TANIZAWA Katsuyuki
    The Institute of Scientific and Industrial Research, Osaka University The Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST) Beacle, Inc.
  • KURODA Shun'ichi
    The Institute of Scientific and Industrial Research, Osaka University The Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST) Beacle, Inc.

Bibliographic Information

Other Title
  • 生体内ピンポイント投与を可能にするバイオナノカプセル
  • セイタイナイ ピンポイント トウヨ オ カノウ ニ スル バイオナノカプセル
  • Bio-nanocapsules for in vivo pinpoint drug delivery

Search this article

Description

To maximize the beneficial effects and minimize the side effect of drugs, DDS (drug delivery system) has been attracted many researchers in the recent drug development. Especially, the in vivo pinpoint delivery system for drugs is very important and key technology for developing the next generations of anti-cancer drugs and gene therapies. Bio-nanocapsule (BNC) is recombinant yeast-derived hepatitis B virus surface antigen particle, which has been used as a recombinant hepatitis B vaccine for the last 20 years in the world. BNC can incorporate various materials (chemical compounds, proteins, genes, siRNA, etc) by the fusion with liposome, and deliver them to the organs and tissues in vivo specifically by the action of bio-recognition molecules on the BNC's surface. The transfection efficiency is significantly higher than that of liposome, because BNC harbors the complete set of hepatitis B virus infection machinery. Recently, we succeeded in the in vivo retargeting of BNC by displaying either antibody or homing peptide, less than 10 amino acid residues for in vivo targeting. BNC is a hybrid of liposome and virus, and very flexible system for in vivo retargeting. BNC might be very promising carriers in the next generation of DDS.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 127 (5), 797-805, 2007-05-01

    The Pharmaceutical Society of Japan

Citations (2)*help

See more

References(70)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top